# DDX3X
## Overview
Mutations in the DDX3X gene, which encodes an RNA helicase involved in various aspects of RNA metabolism, have significant implications in B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and other related malignancies and are particularly enriched within MYC-translocated tumors. These mutations are predominantly loss-of-function (LOF) mutations, affecting the helicase domain of the protein.<sup>1</sup> Missense mutations are predominantly found in male patients and rarely in females, hence showing a sex-specific pattern.<sup>2</sup> 

## Relevance tier by entity

|Entity|Tier|Description                           |
|:------:|:----:|--------------------------------------|
|BL    |1-a | aSHM target and high-confidence BL gene               |
|DLBCL |1-a | aSHM target and high-confidence DLBCL gene            |
|FL    |2-a | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source               |frequency (%)|
|:------:|:---------------------:|:-------------:|
|BL    |GAMBL genomes+capture|44.34        |
|BL    |Thomas cohort        |48.70        |
|BL    |Panea cohort         |39.60        |
|DLBCL |GAMBL genomes        | 8.80        |
|DLBCL |Schmitz cohort       | 4.68        |
|DLBCL |Reddy cohort         | 4.50        |
|DLBCL |Chapuy cohort        | 5.56        |
|FL    |GAMBL genomes        | 2.54        |

## Mutation pattern and selective pressure estimates

|Entity|aSHM|Significant selection|dN/dS (missense)|dN/dS (nonsense)|
|:------:|:----:|:---------------------:|:----------------:|:----------------:|
|BL    |Yes |Yes                  |19.270          |125.826         |
|DLBCL |Yes |No                   | 3.193          |  8.744         |
|FL    |Yes |No                   |11.136          | 21.489         |

## aSHM regions

|chr_name|hg19_start|hg19_end|region                                                                                          |regulatory_comment|
|:--------:|:----------:|:--------:|:------------------------------------------------------------------------------------------------:|:------------------:|
|chrX    |42800580  |42804184|[intergenic](https://genome.ucsc.edu/s/rdmorin/GAMBL%20hg19?position=chrX%3A42800580%2D42804184)|NA                |

> [!NOTE]
> First described in BL in 2012 by [Schmitz R](https://pubmed.ncbi.nlm.nih.gov/22885699). First described in DLBCL in 2018 by [Schmitz R](https://pubmed.ncbi.nlm.nih.gov/29641966). First described in FL in 2023 by [Dreval K](https://pubmed.ncbi.nlm.nih.gov/37084389)


View coding variants in ProteinPaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/DDX3X_protein.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/DDX3X_protein_hg38.html)

![image](images/proteinpaint/DDX3X_NM_001356.svg)

View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/DDX3X.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/DDX3X_hg38.html)

![image](images/proteinpaint/DDX3X.svg)

## References
1. *Lacroix, M., Beauchemin, H., & Möröy, T. (2022). DDX3: a relevant therapeutic target for lymphoma?. Expert Opinion on Therapeutic Targets, 26, 1037 - 1040. https://doi.org/10.1080/14728222.2022.2166830.*
2. *Gong, C., Krupka, J., Gao, J., Grigoropoulos, N., Giotopoulos, G., Asby, R., Screen, M., Usheva, Z., Cucco, F., Barrans, S., Painter, D., Zaini, N., Haupl, B., Bornelöv, S., Mozos, I., Meng, W., Zhou, P., Blain, A., Forde, S., Matthews, J., Tan, M., Burke, G., Sze, S., Beer, P., Burton, C., Campbell, P., Rand, V., Turner, S., Ule, J., Roman, E., Tooze, R., Oellerich, T., Huntly, B., Turner, M., Du, M., Samarajiwa, S., & Hodson, D. (2021). Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.. Molecular cell. https://doi.org/10.1016/j.molcel.2021.07.041.*
